---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-031053"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:24:56.809020+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Foghorn doses first patient in Phase 1 combo study of FHD-286 for AML

## Summary
- FHD-286 in combination with decitabine or cytarabine for relapsed/refractory AML; first patient dosed.
- Data from the Phase 1 combo study expected in second half of 2024.
- Prior monotherapy study showed blast reductions and ANC recovery across genomic backgrounds.
- Preclinical models with decitabine/cytarabine improved survival vs. single-agent controls.
- Study uses 3+3 dose escalation to assess safety, tolerability, and efficacy.

## SEC filing metadata
- accession: 0001628280-23-031053
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023031053/0001628280-23-031053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023031053/fhtx-20230831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-031053
- JSON: https://secwatch.observer/filing/0001628280-23-031053.json
- Plain text: https://secwatch.observer/filing/0001628280-23-031053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.